|
Daehan Nupharm recorded sustained growth, achieving third-quarter sales of 147.9 billion KRW and an operating profit of 21.2 billion KRW
2022.11.14
|
|---|
|
Daehan Nupharm reported third-quarter sales of approximately 147.9 billion KRW, an 18% increase compared to the same period last year, with an operating profit of 21.2 billion KRW (operating margin of 14.3%). Additionally, the company posted a net profit of 20.8 billion KRW, up 48% year-on-year, boosted by an 8.9 billion KRW income from winning a lawsuit.
The company continues to grow by focusing on improved new drugs, biopharmaceutical development, and veterinary medicines. They plan to launch various pharmaceuticals, health supplements, and animal drugs from the fourth quarter through early next year.
First, the recent launch of the DPP-4 inhibitor for type 2 diabetes patients, including the single-agent 'Teneltin tablet' and the combination drug 'Tenelpomin extended-release tablet', provides new momentum, offering benefits like no risk of hypoglycemia or weight gain and suitability irrespective of kidney function.
Second, enhanced-compliance drugs 'Zero-Be tablet' and 'Cambel Double tablet', which doubles the dosage of the 'Cambel tablet' herbal formula, are expected to be launched in February 2023, improving stability and dosing convenience.
Third, the hospital-exclusive health supplement brand 'Dr. DiNU' will launch in November with four new products including high-purity phosphatidylcholine, Super Arginine 5000, Glutamine 6000, and Immune Alpha Capsule, expanding the health supplement sales channel.
Fourth, Daehan Nupharm is expanding its pet products with the upcoming Q4 launch of 'RS-Pro', a natural ingredient-based supplement improving skin and hair conditions, showing effects on promoting hair growth and alleviating skin issues without steroids.
These initiatives underscore Daehan Nupharm's sustained growth strategy through diverse product innovation across pharmaceuticals, supplements, and veterinary care. |


Home